458 related articles for article (PubMed ID: 12123602)
1. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones?
Muchowski PJ
Neuron; 2002 Jul; 35(1):9-12. PubMed ID: 12123602
[TBL] [Abstract][Full Text] [Related]
2. Protein-misfolding diseases and chaperone-based therapeutic approaches.
Chaudhuri TK; Paul S
FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics approaches in yeast to study amyloid diseases.
Outeiro TF; Muchowski PJ
J Mol Neurosci; 2004; 23(1-2):49-60. PubMed ID: 15126692
[TBL] [Abstract][Full Text] [Related]
4. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
Nagai Y; Fujikake N; Popiel HA; Wada K
Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
[TBL] [Abstract][Full Text] [Related]
5. Modulation of neurodegeneration by molecular chaperones.
Muchowski PJ; Wacker JL
Nat Rev Neurosci; 2005 Jan; 6(1):11-22. PubMed ID: 15611723
[TBL] [Abstract][Full Text] [Related]
6. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
Luo GR; Le WD
Curr Pharm Biotechnol; 2010 Feb; 11(2):180-7. PubMed ID: 20166963
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway.
Jana NR; Nukina N
J Chem Neuroanat; 2003 Oct; 26(2):95-101. PubMed ID: 14599658
[TBL] [Abstract][Full Text] [Related]
8. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
Nagai Y; Popiel HA
Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.
Bohush A; Bieganowski P; Filipek A
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31600883
[TBL] [Abstract][Full Text] [Related]
10. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
Wyttenbach A
J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
[TBL] [Abstract][Full Text] [Related]
11. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
[TBL] [Abstract][Full Text] [Related]
12. Molecular Chaperones in Neurodegenerative Diseases: A Short Review.
Bobori C; Theocharopoulou G; Vlamos P
Adv Exp Med Biol; 2017; 987():219-231. PubMed ID: 28971461
[TBL] [Abstract][Full Text] [Related]
13. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.
Dohm CP; Kermer P; Bähr M
Neurodegener Dis; 2008; 5(6):321-38. PubMed ID: 18309232
[TBL] [Abstract][Full Text] [Related]
14. Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders.
Bose S; Cho J
Ageing Res Rev; 2017 May; 35():155-175. PubMed ID: 27702699
[TBL] [Abstract][Full Text] [Related]
15. Protein folding and misfolding in the neurodegenerative disorders: a review.
Bolshette NB; Thakur KK; Bidkar AP; Trandafir C; Kumar P; Gogoi R
Rev Neurol (Paris); 2014 Mar; 170(3):151-61. PubMed ID: 24613386
[TBL] [Abstract][Full Text] [Related]
16. Role of molecular chaperones in neurodegenerative disorders.
Meriin AB; Sherman MY
Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
[TBL] [Abstract][Full Text] [Related]
17. Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.
Pace MC; Xu G; Fromholt S; Howard J; Crosby K; Giasson BI; Lewis J; Borchelt DR
Acta Neuropathol; 2018 Dec; 136(6):919-938. PubMed ID: 30140941
[TBL] [Abstract][Full Text] [Related]
18. Emerging roles of J proteins in neurodegenerative disorders.
Gibbs SJ; Braun JE
Neurobiol Dis; 2008 Nov; 32(2):196-9. PubMed ID: 18760363
[TBL] [Abstract][Full Text] [Related]
19. Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases.
Arawaka S; Machiya Y; Kato T
Curr Pharm Biotechnol; 2010 Feb; 11(2):158-66. PubMed ID: 20170473
[TBL] [Abstract][Full Text] [Related]
20. Emerging Targets and Latest Proteomics Based Therapeutic Approaches in Neurodegenerative Diseases.
Fatima MT; Islam Z; Ahmad E; Salahuddin P
Curr Protein Pept Sci; 2018; 19(9):858-875. PubMed ID: 28762306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
